Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared a post on X:
“Here for ESMO25 Berlin and the thoracic buzz is fire: practice-shaping phase 3s in the presidential sessions, next-gen HER2 TKIs (zongertinib, sevabertinib), smarter EGFR strategies, local-therapy intensification), plus peri-op osimertinib updates.”
You can also read: ESMO 2025 Day 1 Highlights Not to Miss
